Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
2.250
+0.030 (1.35%)
At close: Apr 28, 2026, 4:00 PM EDT
2.230
-0.020 (-0.89%)
After-hours: Apr 28, 2026, 7:33 PM EDT
Neumora Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Neumora Therapeutics stock have an average target of 7.50, with a low estimate of 3.00 and a high estimate of 14. The average target predicts an increase of 233.33% from the current stock price of 2.25.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 1 | 2 | 3 | 4 | 4 | 4 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 2 | 2 | 2 | 2 | 2 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 10 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +522.22% | Mar 31, 2026 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +255.56% | Mar 31, 2026 |
| William Blair | William Blair | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Feb 17, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $8 | Buy | Initiates | $8 | +255.56% | Jan 12, 2026 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $4 → $7 | Hold → Buy | Upgrades | $4 → $7 | +211.11% | Dec 1, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
7.71M
EPS This Year
-1.02
from -1.45
EPS Next Year
-0.98
from -1.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 21.0M | ||||||
| Avg | n/a | 7.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.81 | -0.41 | ||||||
| Avg | -1.02 | -0.98 | ||||||
| Low | -1.26 | -1.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.